ReviewCurrent atherosclerosis reports2026
Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDyslipidemia remains a common and treatable risk factor for atherosclerotic cardiovascular disease (ASCVD) in the United States (US) and worldwide. In 2026, the American College of Cardiology (ACC), the American Heart Association (AHA), and other US societies released a new guideline on the management of dyslipidemia. This review summarizes 10 key takeaways in the primary prevention setting from the 2026 multisociety guideline on the evaluation and management of dyslipidemia. RECENT
findingsKey takeaways from the new guideline include early evaluation for dyslipidemia and potential genetic dyslipidemias starting in childhood, with subsequent screening every 5 years after age 19. Adult screening for dyslipidemia with Lp(a) at least once in lifetime and selective use of ApoB testing is also recommended. After obtaining lipid measurements, risk assessment is performed using the PREVENT-ASCVD score to calculate 10-year (and 30-year in adults aged 30-59) ASCVD risk. Considering demographic, clinical and laboratory data as well as coronary calcium scoring in addition to the PREVENT-ASCVD risk score allows for shared decision-making regarding initiation of lipid lowering therapy (LLT), primarily with statins. The new guideline also reintroduces treatment goals for LDL-C, non-HDL-C, and apo B in select cases based on risk category for the primary prevention population. The 2026 ACC/AHA multisociety dyslipidemia guideline incorporates evolving data on dyslipidemia evaluation and management to optimize ASCVD risk. This review describes 10 key highlights from the guideline for the evaluation and management of dyslipidemia in the primary prevention setting.
Indexed as
Identifiers
42295619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.